What we've learned in the 1st 6 months of 2026

What we've learned in the 1st 6 months of 2026

In this episode of Healthcare Logic for Growth, we break down the pivotal trends from the first half of 2026 that every small and start-up healthcare company needs to know. We explore the good news (rebounding venture funding, FDA fast-track vouchers, and digital health pilot programs), the bad news (FDA staffing shortages, drug pricing uncertainty, and OMB grant threats), and the "data trap" catch-22 that is stifling early-stage biotechs. We share 10 actionable steps to help you navigate the next six months with confidence. Sources Referenced in This Episode: - HSBC Innovation Banking – US Healthcare Venture Investment Report: Provided the $60 billion funding data and the trend of investors demanding later-stage traction from seed-stage companies. - PharmaVoice – Life Sciences 2026 Outlook & FDA Staffing Analysis: Sourced the quotes on FDA staffing challenges post-DOGE and the uncertainty surrounding political appointees at the agency. - FDA Official Guidance & Pilot Programs (2026): - Commissioner’s National Priority Voucher Program (Fast-track review). - TEMPO Pilot Program (Enforcement discretion for digital health technologies). - Revised Guidance on Low-Risk Wellness & Clinical Decision Support Software. - CMS – ACCESS Model Demonstration: Source for the outcomes-based reimbursement model for digital health and medical devices. - Federal Register / OMB – Proposed Rule on Grant Cancellations (May 2026): Source for the non-scientific criteria clause affecting SBIR and NIH grants. - White House Executive Orders – Most Favored Nation Pricing & IRA Implementation Updates: Source for drug pricing pressures. - Congressional Bills – Biotech Workforce Development & Biosecure Act: Source for talent pipeline initiatives and supply chain manufacturing restrictions. - Industry Venture Capital Panel Discussions (Q1/Q2 2026) – various: Sourced the "ship at 92%" mentality and the commercial leadership cautionary tale. Follow & Subscribe: Don't miss an episode! Subscribe to Healthcare Logic for Growth on wherever you get your podcasts. Apple Podcasts: https://podcasts.apple.com/us/podcast/healthcare-logic-for-growth/id1890160182 [https://podcasts.apple.com/us/podcast/healthcare-logic-for-growth/id1890160182] Spotify: https://open.spotify.com/show/1YSwyajbIWDkVWwrIPM1j3 [https://open.spotify.com/show/1YSwyajbIWDkVWwrIPM1j3] YouTube: https://www.youtube.com/@HealthcareLogicforGrowth [https://www.youtube.com/@HealthcareLogicforGrowth]   Have a question or topic you'd like us to cover? Reach out to us at eric@lifesciencelogic.com [eric@lifesciencelogic.com] About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ [https://lifesciencelogic.com/] or reach us at Eric@lifesciencelogic.com [Eric@lifesciencelogic.com]. Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.       Healthcare Logic for Growth  ·  Life Science Logic  ·  Eric@lifesciencelogic.com  ·  © 2026 Life Science Logic

What Healthcare Startups Need to Do to Win - and Why So Many Fail

In this episode of Healthcare Logic for Growth, we break down what healthcare startups need to do to succeed - and why so many fail. We cover the five biggest success factors, including solving a real problem, proving outcomes, building the payment model early, fitting into clinical workflows, and scaling with trust. We also look at five common failure patterns, including weak validation, no reimbursement path, long sales cycles, poor workflow fit, and trust breakdowns. We use real-world examples from Omada Health, Oshi Health, Zocdoc, Theranos, and Babylon Health to show what success and failure look like in practice. If you’re building, investing in, or marketing to healthcare startups, this episode is a practical guide to what actually matters. Key Topics - Why healthcare startups are different from consumer tech. - The five things a healthcare startup needs to do to succeed. - The five most common reasons healthcare startups fail. - Lessons from real companies with public-facing data. - Questions founders should ask to stay on track. - A go-forward strategy for building a durable healthcare company. Sources Referenced in This Episode: - AMA case study on Omada Health, highlighting evidence-based care, data-powered coaching, connected devices, and care coordination. - Omada public platform information on outcomes and care delivery. - AMA and related public materials on Oshi Health, including multidisciplinary GI care, outcomes, and cost savings. - Zocdoc’s public milestone update on profitability, cash flow, provider growth, and business model improvements. - STAT’s analysis of why healthcare startups fail, especially around reimbursement, pricing, and operational complexity. - Public materials on Theranos’s failures and regulatory issues. - Public reporting and analysis on Babylon Health’s collapse and reimbursement challenges. About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ [https://lifesciencelogic.com/] or reach us at Eric@lifesciencelogic.com [Eric@lifesciencelogic.com].   Healthcare Logic for Growth  ·  Life Science Logic  ·  Eric@lifesciencelogic.com  ·  © 2026 Life Science Logic

Priced to Win - How Small Life Science Companies Turn the MFN Drug Pricing Disruption Into a Commercial Advantage

The MFN drug pricing framework - what began as voluntary agreements with sixteen of the largest pharmaceutical companies - is now moving toward mandatory rules that will reach smaller biotechs and pharma companies. At the same time, a 100% pharmaceutical tariff takes effect September 29th for smaller manufacturers, with a lower 20% rate available only to companies that have engaged the MFN framework and filed domestic manufacturing plans. BIO International opens at the same time of this published episode, June 22nd. So, in this episode, we flip the script: instead of treating MFN as a threat, we show small life science companies how to turn it into a commercial advantage - with five specific actions you can take starting this week.   Sources Referenced in This Episode: Skadden Arps — "MFN Drug Pricing and Impact on International Life Sciences Licensing Deals" — June 1, 2026 BioTech Briefings / Gibson Dunn — "MFN Drug Pricing in 2026: Voluntary Deals Are Giving Way to Mandatory Rules" — March 2026 Clinical Leader — "U.S. Pharma Tariffs and MFN Become Law After April 2 Update" — April 2026 AJMC — "MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage" — June 2026 BioSpace — "Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026" PharmExec — "What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications" — April 2026 BIO International Convention 2026 — San Diego, June 22–25, 2026 — convention.bio.org White House Council of Economic Advisers — "Savings from Most-Favored-Nation Drug Pricing Policy" — May 2026 About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ [https://lifesciencelogic.com/] or reach us at Eric@lifesciencelogic.com [Eric@lifesciencelogic.com].   Healthcare Logic for Growth  ·  Life Science Logic  ·  Eric@lifesciencelogic.com  ·  © 2026 Life Science Logic

From Innovation to Revenue: How Healthcare Startups Turn a Great Product Into a Real Business

Healthcare is full of great products that never became great businesses. In this first episode of the Healthcare Startup Revenue Series, we break down 4 of the structural barriers that accelerate performance: * Buyer vs. user separation * Long purchasing cycles * The evidence requirement * Economic model misalignment Whether you’re still in your first year of commercial activity or stuck at early customers and unable to scale, this episode gives you a foundation to consider. Sources Referenced: * Rock Health Digital Health Funding Report - https://rockhealth.com/ [https://rockhealth.com/] * HIMSS Healthcare Procurement Stakeholder Research - https://www.himss.org/ [https://www.himss.org/] * Health Care Transformation Task Force - Value-Based Care Contracting Frameworks - https://hcttf.org/ [https://hcttf.org/]   About Life Science Logic: Life Science Logic helps hospitals, HHAs, healthcare associations, small life science and healthcare companies go to market smarter, not more expensively. We combine commercial strategy, competitive intelligence, and planning with a disciplined, cost-conscious approach - delivering the rigor of a top-tier consultancy without the expanded overhead. The result? Our clients cut unnecessary spending, improve commercial efficiency, and give better performance earlier. Ready to spend less and perform better? Learn more at https://lifesciencelogic.com/ [https://lifesciencelogic.com/] or reach us at Eric@lifesciencelogic.com.   Healthcare Logic for Growth  ·  Life Science Logic  ·  Eric@lifesciencelogic.com  ·  © 2026 Life Science Logic

CMS Just Changed the Playbook for GLP-1...Consider the Following

On May 1, 2026, the CMS BALANCE Model went live - opening the door for Medicaid agencies to begin enrolling in a new federal framework that expands GLP-1 coverage for obesity and metabolic disease. The Medicare GLP-1 Bridge follows on July 1st, giving Medicare Part D beneficiaries access to these drugs at $50 per month. Most of the conversation has focused on Novo Nordisk and Eli Lilly. This episode is for everyone else. We break down what BALANCE actually does, what the commercial ecosystem around it looks like for small pharma, biotech, digital health companies, home health agencies, and hospitals - and five specific actions you should be taking right now.   Sources Referenced in This Episode: * KFF - 'What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge' - Updated May 11, 2026 * CMS Innovation Center - BALANCE Model Official Page and Implementation Timeline - cms.gov * CMS - 'Innovation Insight: Affordability of GLP-1s Takes Next Step with BALANCE Model RFAs' - March 9, 2026 * Eli Lilly - Updated Statement on CMMI BALANCE Model and Medicare GLP-1 Bridge - March 2026 * Fierce Healthcare - 'CMS Launching Payment Model to Boost Access to GLP-1s in Medicaid, Part D' - December 2025 * IQVIA - 'Outlook for Obesity in 2026: From Consolidation to Acceleration' - January 2026 * MMM Online - '2026 Is the Year GLP-1s Grow Up' - February 2026 * AJMC - 'MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage' - May 22, 2026   About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ [https://lifesciencelogic.com/] or reach me at Eric@lifesciencelogic.com [Eric@lifesciencelogic.com]. Healthcare Logic for Growth  ·  Life Science Logic  ·  Eric@lifesciencelogic.com  ·  © 2026 Life Science Logic